Alnylam Pharmaceuticals (ALNY) Accumulated Depreciation & Amortization (2017 - 2024)
Historic Accumulated Depreciation & Amortization for Alnylam Pharmaceuticals (ALNY) over the last 13 years, with Q4 2024 value amounting to $270.4 million.
- Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization rose 2119.82% to $270.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $270.4 million, marking a year-over-year increase of 2119.82%. This contributed to the annual value of $270.4 million for FY2024, which is 2119.82% up from last year.
- Per Alnylam Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $270.4 million for Q4 2024, which was up 2119.82% from $223.1 million recorded in Q4 2023.
- In the past 5 years, Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $270.4 million during Q4 2024, and its lowest value of $104.3 million during Q4 2020.
- In the last 5 years, Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $173.4 million in 2022 and averaged $182.3 million.
- In the last 5 years, Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization soared by 3701.38% in 2020 and then soared by 2119.82% in 2024.
- Alnylam Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $104.3 million in 2020, then surged by 34.57% to $140.4 million in 2021, then increased by 23.53% to $173.4 million in 2022, then grew by 28.61% to $223.1 million in 2023, then increased by 21.2% to $270.4 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $270.4 million for Q4 2024, versus $223.1 million for Q4 2023 and $173.4 million for Q4 2022.